Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc. is set to present its novel microparticle formulation, EP-104, at the Controlled Release Society 2024 Annual Meeting in Bologna, Italy. The company, known for its proprietary DiffuSphere™ technology, aims to enhance drug delivery for conditions lacking effective treatments. Their presentation will detail the extended-release benefits of fluticasone propionate, a significant advance in the field of targeted and long-lasting medication delivery.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
